• Contact Us
Wednesday, December 17, 2025
Health Business
Advertisement
  • Home
  • News
    Beyond Bleeding Disorders: Novo Nordisk Foundation’s Bold Shift Brings New Hope for Millions Living with Sickle Cell and Haemophilia in Africa

    Beyond Bleeding Disorders: Novo Nordisk Foundation’s Bold Shift Brings New Hope for Millions Living with Sickle Cell and Haemophilia in Africa

    The Economics of Maternal Death: How Families Pay the Price When Mothers Die

    The Economics of Maternal Death: How Families Pay the Price When Mothers Die

    Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia

    Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia

    Kenya Confronts Escalating Digital Violence against Women as Part of 16 Days of Activism

    Kenya Confronts Escalating Digital Violence against Women as Part of 16 Days of Activism

  • Events
  • Private
    • KHF
    • Providers
  • Government
    • Medical Research
    • Politics & Policy
    • Regulation, Enforcement & Compliance
  • Finance
  • Tech
  • Epaper
  • Videos
  • Home
  • News
    Beyond Bleeding Disorders: Novo Nordisk Foundation’s Bold Shift Brings New Hope for Millions Living with Sickle Cell and Haemophilia in Africa

    Beyond Bleeding Disorders: Novo Nordisk Foundation’s Bold Shift Brings New Hope for Millions Living with Sickle Cell and Haemophilia in Africa

    The Economics of Maternal Death: How Families Pay the Price When Mothers Die

    The Economics of Maternal Death: How Families Pay the Price When Mothers Die

    Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia

    Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia

    Kenya Confronts Escalating Digital Violence against Women as Part of 16 Days of Activism

    Kenya Confronts Escalating Digital Violence against Women as Part of 16 Days of Activism

  • Events
  • Private
    • KHF
    • Providers
  • Government
    • Medical Research
    • Politics & Policy
    • Regulation, Enforcement & Compliance
  • Finance
  • Tech
  • Epaper
  • Videos
No Result
View All Result
Health Business
No Result
View All Result

UNAIDS urges a scaling up of HIV vaccine research to stop new infections

by Health Business
July 5, 2018
in News
0
UNAIDS urges a scaling up of HIV vaccine research to stop new infections
Share This:

By Lilian Okwili

HIV has been a killer disease in the past years, leaving many infected and affected by it. With the introduction of antiretroviral drugs, the number of death and infections caused by HIV has reduced.

According to UNAIDS, there is need to improve and find a vaccine that can be used to stop or prevent its spread because right now it is a big burden to many governments. During the HIV Vaccine Awareness Day, UNAIDS called for an increase in research and investment to find an effective vaccine to protect people against HIV and stop new HIV infections.

In 2016, around 1.8 million people were newly infected with HIV and although the number of new infections has declined in recent years, the world is still far from achieving the UNAIDS Fast-Track Target of reducing new HIV infections to fewer than 500,000 by 2020.

“New HIV infections are not declining fast enough and stopping infections must become a global priority,” said Michel Sidibé, Executive Director of UNAIDS. There are 36.7 million people living with HIV today, all in need of costly treatment for life, which will be difficult to sustain over the long term. To truly end AIDS, it is essential to find an effective HIV vaccine and a cure.

In mid-2017, more than half (20.9 million) of the 36.7 million people living with HIV had access to antiretroviral medicines to keep them alive and well. Over the next decade, efforts will be scaled up so that all people living with HIV can access the life-saving treatment.

Without a cure or a therapeutic vaccine, millions of people will need to be sustained on lifelong treatment. Promising steps have been made in recent years, with four large-scale trials currently under way and exciting developments in the pipeline.

In n ova t i ve a p p ro a c h e s t o immunization are showing great promise in animal models and an ever- increasing array of highly potent broadly neutralizing antibodies have been discovered and can be engineered to persist in the human body so that we may one day be able to prevent HIV infection with a single injection each year.

Safe and effective vaccines have the potential to change the world. Some infectious diseases that were once commonplace, killing millions and leaving countless people with lifelong disabilities have become rare. Smallpox has been eradicated, only 17 people developed polio in 2017 and in 2016 the Pan American Health Organisation declared that measles had been eliminated from the Americas.

An effective, durable, affordable and safe vaccine for HIV would significantly advance efforts to end AIDS. For the past decade, investments have remained steady, at around US$ 900 million per year, which is less than 5 per cent of the total resources needed for the AIDS response. By scaling up investments in HIV vaccine research, diversifying funding and attracting the best scientists from around the world, a vaccine for HIV could become a reality.

Share This:
Previous Post

Kenya receives Sh400 m to buy ARVs for children

Next Post

First Lady calls for increased partnership in delivery of quality healthcare services

Related Posts

Beyond Bleeding Disorders: Novo Nordisk Foundation’s Bold Shift Brings New Hope for Millions Living with Sickle Cell and Haemophilia in Africa
News

Beyond Bleeding Disorders: Novo Nordisk Foundation’s Bold Shift Brings New Hope for Millions Living with Sickle Cell and Haemophilia in Africa

December 16, 2025
The Economics of Maternal Death: How Families Pay the Price When Mothers Die
Medical Research

The Economics of Maternal Death: How Families Pay the Price When Mothers Die

December 16, 2025
Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia
News

Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia

December 12, 2025
Next Post
First Lady calls for increased partnership in delivery of quality healthcare services

First Lady calls for increased partnership in delivery of quality healthcare services

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

No Result
View All Result

Follow Us

Most Read

  • Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia

    Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia

    0 shares
    Share 0 Tweet 0
  • Court Mandates Degree-Level Pharmacists to Run Kenya’s Top Hospitals

    0 shares
    Share 0 Tweet 0
  • Kenya Confronts Escalating Digital Violence against Women as Part of 16 Days of Activism

    0 shares
    Share 0 Tweet 0
Health Business

Health Business contains need-to-know features, news and case studies that explain the administrative and commercial issues affecting healthcare and hospital management. Health Business supports several high profile exhibitions - coverage of which is always timed for maximum impact. Regular topics include ICT, Finance/Funding, Facilities Management, Security, Health & Safety. Contributors range from government ministers through to top-level health administrators and association chairs.

Top Stories

Beyond Bleeding Disorders: Novo Nordisk Foundation’s Bold Shift Brings New Hope for Millions Living with Sickle Cell and Haemophilia in Africa

Beyond Bleeding Disorders: Novo Nordisk Foundation’s Bold Shift Brings New Hope for Millions Living with Sickle Cell and Haemophilia in Africa

December 16, 2025
The Economics of Maternal Death: How Families Pay the Price When Mothers Die

The Economics of Maternal Death: How Families Pay the Price When Mothers Die

December 16, 2025
Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia

Novo Nordisk Haemophilia Foundation Expands Mandate to Include Sickle Cell Disease and Thalassemia

December 12, 2025

Interests

  • Events
  • Finance
  • Government
  • Magazines
  • Medical Research
  • News
  • Politics & Policy
  • Providers
  • Public Health
  • Regulation, Enforcement & Compliance
  • Technology
  • Videos

Follow Us

  • Contact Us

© 2019 | Site by Mark & Ryse.

No Result
View All Result
  • Home
  • News
  • Events
  • Private
    • KHF
    • Providers
  • Government
    • Medical Research
    • Politics & Policy
    • Regulation, Enforcement & Compliance
  • Finance
  • Tech
  • Epaper
  • Videos

© 2019 | Site by Mark & Ryse.